^
    1year
    CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=27, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Sep 2026 | Trial primary completion date: Nov 2025 --> Sep 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    anti-CD33 CAR T
    over1year
    CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=27, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Aug 2023
    Enrollment open • Trial initiation date • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    anti-CD33 CAR T
    over1year
    Combining Anti-CD33 Chimeric Antigen-Receptor T Cells with the Hypomethylating Agent Decitabine to Treat Acute Myeloid Leukemia (ASGCT 2023)
    Acute myeloid leukemia (AML) is the most common acute leukemia in adults, causing >10,000 deaths per year in the United States. Moreover, DAC treatment resulted in downregulation of DNA repair pathways, β-Catenin, and Notch signaling pathways.Taken together, we found that the antileukemia activity of CD33 CAR T cells was enhanced by pretreatment of leukemia cells with DAC. This combination represents a clinically relevant therapy for the treatment of patients with r/r AML.
    CAR T-Cell Therapy
    |
    DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • CD33 (CD33 Molecule) • CD4 (CD4 Molecule) • DNMT1 (DNA methyltransferase 1) • DNMT3B (DNA Methyltransferase 3 Beta)
    |
    decitabine • anti-CD33 CAR T
    almost2years
    CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, City of Hope Medical Center
    New P1 trial • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    anti-CD33 CAR T